Brooklyn ImmunoTherapeutics appoints Heather B. Redman and Erin S. Enright to board

Ernexa Therapeutics Inc.

Board expanded from 5 to 6; Redman and Enright appointed Jan 14, 2022.
Redman is Managing Partner at Flying Fish Partners; Enright is Managing Member at Prettybrook Partners.
Each received option for 67,000 shares of common stock under 2020 Plan, vesting over 3 years.
Redman joins Compensation and Nominating/Governance Committees; Enright chairs Audit Committee.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Erin S. Enright

Director

ERNA · Ernexa Therapeutics Inc.

Effective: 2022-01-14
Filed: January 20, 2022, 6:59 PM ET

On January 14, 2022, the board of directors (the “Board”) of Brooklyn ImmunoTherapeutics, Inc., a Delaware corporation (the “Company”), expanded its size from five to six directors and appointed Heather B. Redman and Erin S. Enright as new directors with immediate effect to fill the existing vacancy on the Board and the new vacancy resulting from the increase in the Board’s size.

Appointed

Heather B. Redman

Director

ERNA · Ernexa Therapeutics Inc.

Effective: 2022-01-14
Filed: January 20, 2022, 6:59 PM ET

On January 14, 2022, the board of directors (the “Board”) of Brooklyn ImmunoTherapeutics, Inc., a Delaware corporation (the “Company”), expanded its size from five to six directors and appointed Heather B. Redman and Erin S. Enright as new directors with immediate effect to fill the existing vacancy on the Board and the new vacancy resulting from the increase in the Board’s size.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Erin S. Enright was appointed as Director at Ernexa Therapeutics Inc..

Action: appointed
Role: Director

Exact text from the filing

On January 14, 2022, the board of directors (the “Board”) of Brooklyn ImmunoTherapeutics, Inc., a Delaware corporation (the “Company”), expanded its size from five to six directors and appointed Heather B. Redman and Erin S. Enright as new directors with immediate effect to fill the existing vacancy on the Board and the new vacancy resulting from the increase in the Board’s size.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Heather B. Redman was appointed as Director at Ernexa Therapeutics Inc..

Action: appointed
Role: Director

Exact text from the filing

On January 14, 2022, the board of directors (the “Board”) of Brooklyn ImmunoTherapeutics, Inc., a Delaware corporation (the “Company”), expanded its size from five to six directors and appointed Heather B. Redman and Erin S. Enright as new directors with immediate effect to fill the existing vacancy on the Board and the new vacancy resulting from the increase in the Board’s size.

View on SEC.gov

Ernexa Therapeutics Inc. filing history →

Source: SEC EDGAR

accession 0001140361-22-002104

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.